Expression of Recombinant Plasmodium falciparum Cysteine-rich Protective Antigen (PfCyRPA) Fragment 26–181 in Escherichia coli BL21 CodonPlus (DE3) RIPL
Abstract
Background: Malaria is a life-threatening infectious disease caused by Plasmodium parasites, transmitted through infected female Anopheles mosquitoes. PfCyRPA (Plasmodium falciparum Cysteine-Rich Protective Antigen) has emerged as a promising vaccine candidate due to its ability to elicit inhibitory antibodies against parasite growth.
Objective: This study aimed to construct recombinant plasmids encoding PfCyRPA fragment 26–181 and express this fragment in Escherichia coli BL21 CodonPlus (DE3) RIPL for cost-effective antigen production.
Methods: The PfCyRPA gene fragment (~480 bp) was amplified from P. falciparum genomic DNA (Jayapura isolate) by PCR. Recombinant plasmids pGEM-T-PfCyRPA 26-181 and pET-16b-PfCyRPA 26-181 were constructed and confirmed via colony PCR, restriction analysis, and sequencing. The pET-16b-PfCyRPA 26-181 was transformed into E. coli BL21 CodonPlus (DE3) RIPL. Protein expression was induced with 0.5 mM IPTG at 37°C, and analyzed by SDS-PAGE and Western blotting.
Results: SDS-PAGE and Western blot analysis demonstrated successful expression of recombinant PfCyRPA fragment 26–181 with a molecular mass of approximately 21.53 kDa, corresponding to the predicted size. The protein was predominantly expressed as inclusion bodies, typical for eukaryotic proteins in prokaryotic systems. Colony PCR and sequencing confirmed correct gene insertion and integrity.
Conclusion: Recombinant PfCyRPA fragment 26–181 was successfully expressed in E. coli BL21 CodonPlus (DE3) RIPL, providing a cost-effective platform for large-scale antigen production. This work establishes a foundational protocol for further immunogenicity research and supports development of this antigen as a potential blood-stage malaria vaccine candidate.
References
Sato S. Plasmodium—a brief introduction to the parasites causing human malaria and their basic biology. Journal of Physiological Anthropology; 40. https://doi.org/10.1186/s40101-020-00251-9.
Direktorat Jenderal Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan RI. Laporan Tahunan 2022 Malaria. 2022. https://malaria.kemkes.go.id/node/187
World Health Organization; World Malaria Report 2022. 2022. https://www.who.int/teams/global-malaria-programme
World Health Organization. Highlights from the Global Malaria Programme: annual report 2024. 2024. https://www.who.int/publications/i/item/9789240107908
Laurens MB. RTS,S/AS01 vaccine (MosquirixTM): an overview. Hum Vaccin Immunother. https://doi.org/10.1080/21645515.2019.1669415.
Somanathan A, Mian SY, Chaddha K, et al. Process development and preclinical evaluation of a major Plasmodium falciparum blood stage vaccine candidate, Cysteine-Rich Protective Antigen (CyRPA). Front Immunol; 13. https://doi.org/10.3389/fimmu.2022.1005332.
Favuzza P, Guffart E, Tamborrini M, et al. Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody. Elife; 6. https://doi.org/10.7554/eLife.20383.
Mian SY, Somanathan A, Chaddha K, et al. Plasmodium falciparum Cysteine-Rich Protective Antigen (CyRPA) Elicits Detectable Levels of Invasion-Inhibitory Antibodies during Natural Infection in Humans. Infect Immun; 90. https://doi.org/10.1128/IAI.00377-21.
Volz JC, Yap A, Sisquella X, et al. Essential Role of the PfRh5/PfRipr/CyRPA Complex during Plasmodium falciparum Invasion of Erythrocytes. Cell Host Microbe 2016; 20: 60–71. doi: https://doi.org/10.1016/j.chom.2016.06.004
Wong W, Huang R, Menant S, et al. Structure of Plasmodium falciparum Rh5–CyRPA–Ripr invasion complex. Nature 2019; 565: 118–121. https://doi.org/10.1038/s41586-018-0779-6
Favuzza P, Dreyer AM, Wittlin S, et al. Cysteine-Rich Protective Antigen (CyRPA) as promising blood-stage candidate protein for inclusion in a malaria subunit vaccine. Malar J; 11. https://doi.org/10.1186/1475-2875-11-s1-p30.
Bustamante LY, Powell GT, Lin Y-C, et al. Synergistic malaria vaccine combinations identified by systematic antigen screening. Proceedings of the National Academy of Sciences 2017; 114: 12045–12050. https://doi.org/10.1073/pnas.1702944114
Reddy KS, Amlabu E, Pandey AK, et al. Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasion. Proc Natl Acad Sci U S A 2015; 112: 1179–1184. https://doi.org/10.1073/pnas.1415466112
Dreyer AM, Matile H, Papastogiannidis P, et al. Passive Immunoprotection of Plasmodium falciparum -Infected Mice Designates the CyRPA as Candidate Malaria Vaccine Antigen . The Journal of Immunology 2012; 188: 6225–6237. https://doi.org/10.4049/jimmunol.1103177
Tamborrini M, Hauser J, Schäfer A, et al. Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models. NPJ Vaccines; 5. https://doi.org/10.1038/s41541-020-0158-9
Rosano GL, Ceccarelli EA. Recombinant protein expression in Escherichia coli: Advances and challenges. Frontiers in Microbiology; 5. https://doi.org/ 10.3389/fmicb.2014.00172
Kaur J, Kumar A, Kaur J. Strategies for optimization of heterologous protein expression in E. coli: Roadblocks and reinforcements. Int J Biol Macromol 2018; 106: 803–822. https://doi.org/10.1016/j.ijbiomac.2017.08.080
Rosano GL, Morales ES, Ceccarelli EA. New tools for recombinant protein production in Escherichia coli: A 5-year update. Protein Science 2019; 28: 1412–1422. https://doi.org/10.3389/fmicb.2014.00172
Francis DM, Page R. Strategies to optimize protein expression in E. coli. Current Protocols in Protein Science. https://doi.org/10.1002/0471140864.ps0524s61
Masduki FF, Hotimah Y, Rani R, et al. Cloning and expression of Plasmodium falciparum lactate dehydrogenase (PfLDH) in Escherichia coli BL21(DE3). Acta Biochimica Indonesiana 2019; 2: 52–57. https://doi.org/10.32889/actabioina.v2i2.39
Schägger H. Tricine–SDS-PAGE. Nat Protoc 2006; 1: 16–22. https://doi.org/10.1038/nprot.2006.4
SnapGene. SnapGene software. www.snapgene.com
Wei H, Therrien C, Blanchard A, et al. The Fidelity Index provides a systematic quantitation of star activity of DNA restriction endonucleases. Nucleic Acids Res 2008; 36: e50–e50. https://doi.org/10.1093/nar/gkn182
Assadi-Porter FM, Patry S, Markley JL. Efficient and rapid protein expression and purification of small high disulfide containing sweet protein brazzein in E. coli. Protein Expr Purif 2008; 58: 263–268. https://doi.org/10.1016/j.pep.2007.11.009
Kopanic JL, Al-Mugotir M, Zach S, et al. An Escherichia coli strain for expression of the connexin45 carboxyl terminus attached to the 4th transmembrane domain. Front Pharmacol; 4. https://doi.org/10.3389/fphar.2013.00106
Sockolosky JT, Szoka FC. Periplasmic production via the pET expression system of soluble, bioactive human growth hormone. Protein Expr Purif 2013; 87: 129–135. https://doi.org/10.1016/j.pep.2012.11.002
Macario AJL, Conway de Macario E. Chaperone Proteins and Chaperonopathies. In: Encyclopedia of Stress. Elsevier, 2007, pp. 438–444.
Nosaki S, Miura K. Transient expression of recombinant proteins in plants. 2021, pp. 193–203. https://doi.org/10.1016/bs.mie.2021.04.021
de Marco A. Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli. Microb Cell Fact 2009; 8: 26. https://doi.org/10.1186/1475-2859-8-26
Fernandes B, Sousa M, Castro R, et al. Scalable Process for High-Yield Production of PfCyRPA Using Insect Cells for Inclusion in a Malaria Virosome-Based Vaccine Candidate. Front Bioeng Biotechnol; 10. https://doi.org/10.3389/fbioe.2022.879078
Ahn M, Song M, OH E, et al. Production of therapeutic proteins with baculovirus expression system in insect cell. Entomol Res; 38. Epub ahead of print 19 November 2008. https://doi.org/10.1111/j.1748-5967.2008.00177.x
Jarvis DL. Developing baculovirus-insect cell expression systems for humanized recombinant glycoprotein production. Virology 2003; 310: 1–7. https://doi.org/10.1016/S0042-6822(03)00120-X
Copyright (c) 2025 Fifi Fitriyah Masduki, Aurelia Galih Prameswari, Fernita Puspasari, Ihsanawati Ihsanawati, Dessy Natalia
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
